Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
NCT ID: NCT03218852
Last Updated: 2017-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
133 participants
INTERVENTIONAL
2016-12-31
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
NCT01758120
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
NCT05510323
Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
NCT02662283
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
NCT03466801
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
NCT04020328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
prednisone and cyclophosphamide
1. prednisone(0.5mg/kg/day\*6 months)
2. cyclophosphamide(1g intravenous use,per 1 month\*6months);
3. supportive care,including ACE-I or ARBs and blood pressure control
prednisone and cyclophosphamide
Prednisone and cyclophosphamide are both administered to participants in this group.
prednisone alone
1. prednisone(0.5mg/kg/day\*6months);
2. supportive care,including ACE-I or ARBs and blood pressure control
prednisone alone
Prednisone is administered to participants in this group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prednisone and cyclophosphamide
Prednisone and cyclophosphamide are both administered to participants in this group.
prednisone alone
Prednisone is administered to participants in this group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-70 years old
* elevated serum Creatinine and less than 3.0mg/dl
* with a written consent from participants to receive prednisone and/or cyclophosphamide
Exclusion Criteria
* contraindications for the treatment of prednisone and/or cyclophosphamide
* any treatment with steroids or immunosuppressive drugs prior to this study
* acute deterioration of renal function(including those of glomerular origin)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Shi
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong General Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GGH2012-36-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.